Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.

White House’s landmark deal with Novo Nordisk and Eli Lilly will cut costs from at least $1,000 to about $350

The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.